Civica Rx
| Company type | Nonprofit |
|---|---|
| Industry | Pharmaceutical manufacturing |
| Founded | 2018 |
| Headquarters | Petersburg, Virginia , United States |
Area served | United States |
| Products | Generic medications, sterile injectables, prefilled insulin pens |
Civica Rx is a nonprofit manufacturer specializing in generic drug production, established in 2018 by prominent U.S. health systems and philanthropic organizations to address drug shortages and curb price inflation within the United States. Its core objective is to ensure the availability and affordability of high-quality generic medications, operating under a Healthcare Utility business framework.
Medications offered by Civica are highly valued by hospital pharmacists and physicians alike. Participating hospitals secure their supply through long-term purchasing contracts, which contribute to market stability. To mitigate supply interruptions, Civica maintains an inventory buffer equivalent to six months of demand. Currently, Civica serves 55 health systems and approximately 1,500 hospitals—accounting for about one-third of all licensed hospital beds across the U.S.—and also provides medications to the U.S. Departments of Veterans Affairs and Defense, as well as “340B” hospitals that cater to underserved populations.
By April 2025, Civica had distributed in excess of 210 million vials and syringes of essential medications, sufficient to treat over 97 million patients nationwide.
To expand domestic generic drug manufacturing capabilities, Civica is constructing a new sterile injectable facility spanning 140,000 square feet in Petersburg, Virginia, representing a $124.5 million investment. This manufacturing site is designed to produce up to 90 million vials and 50 million prefilled syringes annually, including a specialized high-speed production line for prefilled insulin pens.
The organization’s initial private-label shipment was vancomycin delivered to Riverton Hospital—part of founding member Intermountain Healthcare—in October 2019. Throughout the COVID-19 pandemic, 11 out of more than 80 medications supplied by Civica played a critical role in patient treatment, including neuromuscular blockers, sedatives, and analgesics essential for ventilated individuals.
Partnerships and deals
In 2020, Civica joined forces with 18 Blue Cross Blue Shield plans to introduce CivicaScript, a program aimed at lowering the costs of expensive generic drugs at retail pharmacies. CivicaScript extends the company’s mission by offering affordable, high-quality outpatient generics directly to consumers. The inaugural product under this initiative was abiraterone acetate 250 mg for prostate cancer treatment, priced approximately $3,000 less per month compared to the average Medicare Part D expense.
January 2021 saw Civica Rx announce plans for a new essential medicines manufacturing facility in Virginia in collaboration with Phlow Corp. This plant will focus on producing sterile injectable drugs vital for hospital care related to COVID-19, emergency interventions, surgical procedures, and other critical health conditions. Civica is part of a government-funded partnership involving Phlow Corp, the Medicines for All Institute at Virginia Commonwealth University, and AMPAC Fine Chemicals.
In March 2023, California Governor Gavin Newsom revealed a $50 million agreement spanning ten years with Civica to provide affordable insulin—in both vial and prefilled pen formats—through the CalRx initiative aimed at delivering low-cost prescription medications throughout California.